Literature DB >> 2742400

Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively.

A J Swaak1, J C Nossent, W Bronsveld, A van Rooyen, E J Nieuwenhuys, L Theuns, R J Smeenk.   

Abstract

The incidence of exacerbations in the disease course was investigated in 110 patients with systemic lupus erythematosus (SLE) who were studied prospectively at our institute for lupus research. At the time of disease onset and diagnosis the male patients were much older than the female patients (about 10 years); exacerbation frequency during follow up was increased in the male patients. The follow up data showed that if a patient with SLE was prone to develop an exacerbation this mostly took place within the first five years of follow up. It could be calculated that after fulfilling the American Rheumatism Association criteria only 56% (62/110) of the patients developed a subsequent exacerbation. Features at the time of diagnosis, distinguishing those patients who developed a subsequent exacerbation from those who did not, were haemolytic anaemia, the presence of anti-Sm antibodies, and a falsely positive serological test for syphilis. At the time of diagnosis, however, the prevalences of these features were low; for haemolytic anaemia, anti-Sm antibodies, and a falsely positive serological test for syphilis they amounted to 40%, 5%, and 12% respectively.

Entities:  

Mesh:

Year:  1989        PMID: 2742400      PMCID: PMC1003787          DOI: 10.1136/ard.48.6.455

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

1.  Chest roentgenographic changes in systemic lupus erythematosus.

Authors:  J G BULGRIN; E L DUBOIS; G JACOBSON
Journal:  Radiology       Date:  1960-01       Impact factor: 11.105

Review 2.  The natural history of systemic lupus erythematosus by prospective analysis.

Authors:  D Estes; C L Christian
Journal:  Medicine (Baltimore)       Date:  1971-03       Impact factor: 1.889

3.  Significance of persisting serologic abnormalities in SLE.

Authors:  R W Lightfoot; G R Hughes
Journal:  Arthritis Rheum       Date:  1976 Sep-Oct

4.  Fever in systemic lupus erythematosus.

Authors:  N I Stahl; J H Klippel; J L Decker
Journal:  Am J Med       Date:  1979-12       Impact factor: 4.965

5.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

6.  Prognostic value of anti-dsDNA in SLE.

Authors:  A J Swaak; J Groenwold; L A Aarden; L W Statius van Eps; E W Feltkamp
Journal:  Ann Rheum Dis       Date:  1982-08       Impact factor: 19.103

7.  Corticosteroid treatment in systemic lupus erythematosus. Survival studies.

Authors:  J D Urman; N F Rothfield
Journal:  JAMA       Date:  1977-11-21       Impact factor: 56.272

8.  Detection of anti-dsDNA as diagnostic tool.

Authors:  A J Swaak; J Groenwold; L A Aarden; T E Feltkamp
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103

9.  Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980.

Authors:  D J Wallace; T E Podell; J M Weiner; M B Cox; J R Klinenberg; S Forouzesh; E L Dubois
Journal:  Am J Med       Date:  1982-02       Impact factor: 4.965

10.  Systemic lupus erythematosus--survival patterns. Experience with 609 patients.

Authors:  D J Wallace; T Podell; J Weiner; J R Klinenberg; S Forouzesh; E L Dubois
Journal:  JAMA       Date:  1981-03-06       Impact factor: 56.272

View more
  12 in total

Review 1.  The use of laboratory tests in the diagnosis of SLE.

Authors:  W Egner
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

Review 2.  Outcome and survival in systemic lupus erythematosus.

Authors:  B Bresnihan
Journal:  Ann Rheum Dis       Date:  1989-06       Impact factor: 19.103

Review 3.  Arthritis and epidemiology in Europe.

Authors:  A K Thould
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

4.  Anti-heparan sulphate reactivity in sera from patients with systemic lupus erythematosus with renal or non-renal manifestations.

Authors:  R M Termaat; K Brinkman; J C Nossent; A J Swaak; R J Smeenk; J H Berden
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

5.  Systemic lupus erythematosus--changing disease patterns in the disease course. Dutch experience with 110 patients studied prospectively.

Authors:  A J Swaak; W Bronsveld; E J Nieuwenhuys; J C Nossent; R J Smeenk
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

6.  Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients.

Authors:  N D Hopkinson; M Doherty; R J Powell
Journal:  Ann Rheum Dis       Date:  1994-10       Impact factor: 19.103

7.  Changes in clinical features of patients with systemic lupus erythematosus followed prospectively over 2 decades.

Authors:  A J Swaak; E J Nieuwenhuis; R J Smeenk
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

Review 8.  Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review.

Authors:  Noémie Gensous; Aurélie Marti; Thomas Barnetche; Patrick Blanco; Estibaliz Lazaro; Julien Seneschal; Marie-Elise Truchetet; Pierre Duffau; Christophe Richez
Journal:  Arthritis Res Ther       Date:  2017-10-24       Impact factor: 5.156

9.  Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort.

Authors:  Noémi Györi; Ioanna Giannakou; Katerina Chatzidionysiou; Laurence Magder; Ronald F van Vollenhoven; Michelle Petri
Journal:  Lupus Sci Med       Date:  2017-02-08

10.  Patient Perspective on Using Digital Resources to Address Unmet Needs in Systemic Lupus Erythematosus.

Authors:  Jennifer H Ra; Jerik Leung; Elizabeth A Baker; Alfred H J Kim
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-09-08       Impact factor: 5.178

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.